Chelator-targeting ligand conjugates for cardiovascular imaging

A method of imaging a site in a heart of a subject to detect cardiovascular disease, wherein the subject has been previously subjected to stress and imaged using nuclear imaging to determine whether there is a region of decreased perfusion suggesting the presence of ischemia, the method comprising:

• (a) administering to the patient at rest a detectable amount of a radionuclide-labeled chelator-glucose analog conjugate;
• and
• (b) imaging the heart of the subject to detect a signal generated by the radionuclide-labeled chelator-glucose analog conjugate,
• wherein a signal generated by the radionuclide-labeled chelator-glucose analog conjugate in the region of the heart that showed decreased perfusion on the MPI imaging study is a region of suspected myocardial ischemia.

A method of distinguishing a false positive nuclear cardiology scan from a true positive nuclear cardiology scan, comprising:

• a) administering to a subject a detectable amount of a radionuclide-labeled chelator-glucose analog conjugate, wherein the subject has had a positive nuclear cardiology scan, and a site of diminished signal was identified on the nuclear cardiology scan that is suggestive of cardiac ischemia;
• and
• (b) imaging the heart of the subject to detect the presence of a signal generated by the radionuclide-labeled chelator-glucose analog conjugate,
• wherein the presence of a signal that is more intense than surrounding heart tissue is indicative of a true positive nuclear cardiology scan, and absence of a signal that is more intense than surrounding heart tissue is indicative of a false positive nuclear cardiology scan.